ESTRO 2025 - Abstract Book

S1025

Clinical – Head & neck

ESTRO 2025

References: 1. de Leeuw ALMP, Giralt J, Tao Y, Benavente S, France Nguyen TV, Hoebers FJP, et al. A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE). Radiother Oncol. 2024;196 (April).

2331

Digital Poster PATTERNS OF FAILURE IN PORT IN ADENOID CYSTIC CARCINOMA: 13 YEARS EXPERIENCE Pablo Araguas 1 , Marc Juarez 1 , Berta Pique 2 , Isabel Linares 1 , Monica Arguis 3 , David Gomez 4 , Mauricio Murcia 4 , Meritxell Arenas 4 , Alicia Lozano 1 1 Radiation Oncology department, Institut calata d’oncologia, Barcelona, Spain. 2 Department of Pathology, Hospital Universitari Sant Joan de Reus, Reus, Spain. 3 Hospital Sant Joan de Reus, Hospital Universitari Sant Joan de Reus, Reus, Spain. 4 Radiation Oncology department, Hospital Universitari Sant Joan de Reus, Reus, Spain Purpose/Objective: The purpose of the study was to investigate the patterns of locorregional and distance relapse after PORT in adenoid cystic carcinoma (ACC) in salivary gland carcinomas. Material/Methods: A total of 98 patients with non metastatic head and neck ACC 43 underwent PORT between 2010 and 2023 in two main hospitals in Catalunya Patients received 3D-CRT (12%) and IMRT (88%). Mean total dose to the tumor bed was 64Gy ( range from 60-70Gy). Only two of them received concomitant radiochemotherapy. Statistic Kaplan-Meier, log-rank Results: Patients characeristics are detailed in table 1 Median OS was 9.98 years and the median PFS was 3.22 years. At 6 years, OS and PFS rates were 60% and 25% respectively. A total of 72.09% recurred. Locally 20.93%, distant 48,84% and local and distant in 2.32 %, nevertheless without regional recurreces. No significant differences were found on OS between failure and no failure groups (log-rank p = 0.093) Among risk factors for disease recurrence, Tstage were significant independent prognostic factor revealed from multivariante cox (HR 4,179, CI 95% 1.264-13,82, p=0.019), and solid histology from OS (HR 5,33, CI 95% 1.041-27,38, p=0.045). Conclusion: Despite of the majority of patients had locally advanced disease, IPN, solid histology and R1 resection, local control was excellent In 13 years of follow up we found almost 50% of patients with distant metastasis, and these data open the question to investigate genomic and molecular profiles to potential target therapies.

Keywords: adenoyd cystic carcinoma